

Receipt

**PATENT** 

† HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231 ON THE DATE INDICATED BELOW.

Louis Drain

DATE:

Merch 20, 2001

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re

: Patent Application of

: Eugene Roussel

. Lugene Rouss

Appln. No.

: 09/756,978

Filed

: January 9, 2001

Attorney Docket No.

: Office of Initial Patent Examination

10582-1

For

THERAPEUTIC MODULATION OF

: THE TUMOR INFLAMMATORY

: RESPONSE

### REQUEST FOR CORRECTED FILING RECEIPT

Attached is the original Filing Receipt for the above-identified patent application.

### In the Name of the Applicant:

Please change the Applicant's name from "Roussel Eugene" to

--Eugene Roussel--.

Please make this correction and provide us with a Corrected Filing Receipt.

Respectfully submitted,

**EUGENE ROUSSEL** 

20 March 200,

(date)

GARY D. COLBY, Ph.D., J.D.

Registration No. 40,961

AKIN, GUMP, STRAUSS, HAUER & FELD, L.L.P.

One Commerce Square

2005 Market Street, Suite 2200

Philadelphia, PA 19103

Telephone: (215) 965-1200 Direct: (215) 965-1285

Facsimile: (215) 965-1210 E-mail: gcolby@akingump.com

GDC:lcd Enclosure

PHL 114803 v1





AUG 0 3. 2001

# UNITED STATES PATENT AND TRADEMARK OFFICE TECH CENTER 1600/2900

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 2023I
www.uspto.gov

 APPLICATION NUMBER
 FILING DATE
 GRP ART UNIT
 FIL FEE REC'D
 ATTY DOCKET NO
 DRAWINGS
 TOT CLAIMS
 IND CLAIMS

 09/756,978
 01/09/2001
 1645
 827
 210582.0001/1US
 68 ?
 4 ~


**CONFIRMATION NO. 6809** 

000570

AKIN, GUMP, STRAUSS, HAUER & FELD

ONE COMMERCE SQUARE 2005 MARKET STREET, SUITE 2200

PHILADELPHIA, PA 19103



Date Mailed: 02/21/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Roussel Eugene, Houston, TX; EUGENE ROUSSEL

Continuing Data as Claimed by Applicant

Foreign Applications

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

\*\* SMALL ENTITY \*\*

Title

Therapeutic modulation of the tumor inflammatory response

**Preliminary Class** 

424

COPY



AUG 0 3 2001

### UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

UNITED STATES PATENT AND TRADEMARK OFFICE WASHINGTON, D.C. 20231

FIL FEE REC'D ATTY.DOCKET.NO DRAWINGS TOT CLAIMS IND CLAIMS FILING DATE GRP ART UNIT APPLICATION NUMBER 01/09/2001 / 1645 827 210582.0001/1US / 09/756,978 🗸


**CONFIRMATION NO. 6809** 

000570

AKIN, GUMP, STRAUSS, HAUER & FELD.

ONE COMMERCE SQUARE 2005 MARKET STREET, SUITE 2200

PHILADELPHIA, PA 19103



Date Mailed: 02/21/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Roussel Eugene, Houston, TX;

Continuing Data as Claimed by Applicant

**Foreign Applications** 

2001 MAR

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

\*\* SMALL ENTITY \*\*

**Title** 

Therapeutic modulation of the tumor inflammatory response  $\sqrt{\phantom{a}}$ 

**Preliminary Class** 

424

Data entry by : MERSO, WOSSENE

Team : OIPE

Date: 02/21/2001





# LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

#### **GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CRF 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

### NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15 (b).

### PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

2001 NL ROOI









## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE

Washington, D.C. 2023I www.uspto.gov

169

**CONFIRMATION NO. 6809** 

Bib Data Sheet

SERIAL NUMBER 09/756,978	FILING DATE 01/09/2001 RULE	CLASS XXX		GROUP ART UNIT 2899		ATTORNEY DOCKET NO. 210582.0001/1US		i		
APPLICANTS							R	CEIVE	D	
Eugene Roussel, Houston, TX;							AUG 0 3 2001			
** CONTINUING DA	TA ***************	*				7			1	
** FOREIGN APPLI	CATIONS ***********	t na n				ł	ECH (	CENTER 1600/2	? <b>9</b> 00	
IF REQUIRED, FOR ** 05/01/2001	EIGN FILING LICENSE	GRANTED ** SN	/ALL E	NTITY *	*					
Foreign Priority claimed		T	ITRY	SHEETS DRAWING 0		TOTAL CLAIMS 68		INDEPENDENT CLAIMS 4		
ADDRESS 000570										
TITLE										
Therapeutic modulat	ion of the tumor inflamm	atory response								
					☐ All Fees					
					☐ 1.16 Fees (Filing)					
FILING FEE FEI	FEES: Authority has been given in Paper Noto charge/credit DEPOSIT ACCOUN			☐ 1.17 Fees ( Processing Ext. of						
RECEIVED No.				VT U	• • • • • • • • • • • • • • • • • • •					
892 No.	No for following:				1.18 Fees (Issue)					
					Other					
					☐ Credit					